Champions Oncology, Inc. (CSBR) stock
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 9/30251% above fair value
$4.65−0.13 (-2.72%)
Close on Nov 12, 2026Market cap $64.72MP/E –Yield –
Champions Oncology EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Champions Oncology's EV/EBITDA was 216.3× on Nov 11, 2026, against 13.6× a year earlier. Over the last 5 years it ranged from 9.6× to 765.5×, with a median of 82.1×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 216.3× | +192.5 |
| 2025 | Dec 31, 2025 | 23.9× | −86.1 |
| 2024 | Dec 31, 2024 | 110.0× | +85.5 |
| 2023 | Feb 28, 2023 | 24.6× | +0.9 |
| 2022 | Dec 30, 2022 | 23.7× | −46.9 |
| 2021 | Dec 31, 2021 | 70.5× | −82.2 |
| 2020 | May 29, 2020 | 152.8× | +84.8 |
| 2019 | Aug 30, 2019 | 67.9× | −81.4 |
| 2018 | Dec 31, 2018 | 149.3× | – |
See a number that looks wrong?